布地奈德对哮喘有多大的效果？

(Budesonide, Budenofalk) has significant lipophilicity and is rapidly absorbed in the intestine due to good tissue permeability. Compared to classical GCS, budesonide has a very high affinity for the receptor. Because of these properties, Budesonide (Budenofalk) has a purposeful local action. About 90% of Budesonide (Budenofalk) is metabolized in the liver on first pass, and only about 10% has systemic effects. Of this amount, 90% of budesonide is bound to albumin, and for this reason it has a biologically inert form. Budesonide is approved for use in patients with glucocorticoid-dependent or -independent bronchial asthma and asthmatic chronic bronchitis.

The MIST trial enrolled children with modified API positivity, recurrent wheezing, and ≥1 exacerbation in the past year but with low severity (defined as infrequent albuterol use and infrequent nocturnal awakenings between exacerbations). All subjects first received pretreatment with nightly placebo doses of budesonide inhalation suspension for 2 weeks (run-in period) and albuterol if necessary, and then received 52 weeks (treatment period) of randomized treatment. The intermittent treatment group (n=139) received 1 mg Budesonide (Budenofalk) inhalation suspension twice a day for 7 days after the respiratory disease was diagnosed; the daily treatment group (n=139) received 0.5 mg Budesonide (Budenofalk) inhalation suspension every night. Each group was also given a corresponding placebo dose of the drug.

The results showed that the incidence rates of asthma exacerbation in the Budesonide (Budenofalk) treatment group and the intermittent treatment group were 0.97/(patient·year) and 0.95/(patient·year) respectively, and the relative incidence rate in the intermittent treatment group was 0.99. The incidence rates of non-serious adverse events and serious adverse events were also similar between the two groups, but the average cumulative exposure of budesonide (Budenofalk) in the intermittent treatment group was significantly smaller than that in the daily treatment group (45.7 mg vs 149.9 mg). 

The above is the effect of (Budesonide, Budenofalk) on asthma provided by our medical companion travel overseas medical consulting service company. Patients must follow the doctor's instructions and use them rationally.